Four foreign firms producing OTC drugs susceptible to diethylene glycol and ethylene glycol substitution failed to reply to US regulators’ recent requests for information on their good manufacturing practices compliance while another six were warned about GMP violations concerning testing for the substances.
Warning letters recently published by the Food and Drug Administration include two to firms in India and two in South...






